# FFAR2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - FFAR2 is a G protein-coupled receptor (GPCR) encoded by the *FFAR2* gene on chromosome 19q13.12, acting as the primary sensor for short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate. It signals through both Gαi/o and Gαq/11 pathways, as well as β-arrestin recruitment, integrating nutritional status with immune function. - The receptor's structure features a canonical seven-transmembrane helical bundle with an orthosteric binding pocket critical for SCFA recognition, involving key residues such as Arg-180, His-140, and Tyr-238. Active-state cryo-EM structures reveal distinct interfaces for Gαi/o and Gαq/11 coupling, enabling biased signaling. - FFAR2 plays a critical role in immune cell trafficking and inflammatory resolution, with Gαi/o signaling inhibiting pro-inflammatory cytokine production in neutrophils and Gαq/11 signaling promoting monocyte chemotaxis. β-arrestin recruitment activates ERK1/2, contributing to cell proliferation and survival. - Dysregulation of FFAR2 is implicated in numerous diseases, including obesity, type 2 diabetes mellitus (T2DM), inflammatory bowel disease (IBD), colorectal cancer (CRC), and allergic airway inflammation. Specific single nucleotide polymorphisms (SNPs) like rs1801844 (p.Arg111His) are associated with increased T2DM risk due to impaired Gαq signaling. - Rare loss-of-function mutations, such as p.Arg180Cys (R180C), lead to severe immune deficiencies characterized by recurrent bacterial infections due to impaired neutrophil function. Somatic mutations, like p.Arg180His (R180H) in colorectal cancer, can promote oncogenesis through biased signaling. - FFAR2 is a high-priority therapeutic target, with investigational orthosteric agonists (e.g., AZD-3965) and negative allosteric modulators (e.g., GLPG0974) in clinical development for metabolic and inflammatory conditions, though achieving selective and effective modulation remains a challenge. --- ## Executive Summary & Key Metadata The Free Fatty Acid Receptor 2 (FFAR2), also historically designated GPR43, is a class A G protein-coupled receptor (GPCR) that serves as the primary physiological sensor for short-chain fatty acids (SCFAs), particularly acetate (C2), propionate (C3), and butyrate (C4). Encoded by the *FFAR2* gene on chromosome 19, this receptor is a master regulator of metabolic homeostasis, immune cell trafficking, inflammatory resolution, and gut-brain axis communication. Its unique coupling to both Gαi/o and Gαq/11 signaling cascades, alongside β-arrestin-mediated scaffolding, positions FFAR2 as a critical node integrating nutritional status with immune competence. Clinically, *FFAR2* has been implicated in obesity, type 2 diabetes mellitus (T2DM), inflammatory bowel disease (IBD), colorectal cancer (CRC), allergic airway inflammation, and sepsis. The receptor is now a high-priority target for the development of orthosteric and allosteric small-molecule modulators, with several investigational compounds in preclinical and early clinical phases. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | FFAR2 | | **UniProt Accession** | O15552 | | **Representative PDB ID** | True (e.g., 8X6D, 8X6E, 8X6F for active-state structures) | | **Chromosomal Locus** | 19q13.12 (GRCh38: chr19:35,558,354-35,562,145; minus strand) | | **Primary Molecular Function** | G protein-coupled receptor for short-chain fatty acids (C2-C4); activates Gαi/o and Gαq/11 pathways; recruits β-arrestins | | **Disease & Pathology Associations** | Obesity, T2DM, IBD (ulcerative colitis, Crohn’s disease), colorectal cancer, asthma, allergic rhinitis, sepsis, atherosclerosis, and neuroinflammation | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *FFAR2* gene is located on the long arm of chromosome 19 at cytogenetic band 19q13.12. In the GRCh38 assembly, the gene spans approximately 3.8 kilobases (kb) of genomic DNA, mapping to coordinates chr19:35,558,354–35,562,145 on the minus (reverse) strand. The gene is embedded within a cluster of structurally related GPCR genes, including *FFAR1* (GPR40), *FFAR3* (GPR41), and *FFAR4* (GPR120), which are arranged in tandem. This genomic clustering suggests an evolutionary origin via serial gene duplication events from a common ancestral SCFA receptor, followed by functional divergence. The intergenic distance between *FFAR2* and *FFAR3* is remarkably short (~1.5 kb), and the two genes share a high degree of sequence identity (~40% at the amino acid level), yet they exhibit distinct ligand selectivity and signaling bias. ### 1.2 Promoter Architecture and Transcriptional Regulation The promoter region of *FFAR2* lacks a canonical TATA box but contains a high-density CpG island spanning the proximal promoter and first exon. This CpG island is subject to dynamic DNA methylation, which has been shown to modulate receptor expression in response to dietary and inflammatory stimuli. Several transcription factor binding sites (TFBS) have been experimentally validated or computationally predicted within the 5' flanking region: - **PPARγ (Peroxisome Proliferator-Activated Receptor Gamma):** A functional PPARγ response element (PPRE) located approximately -1.2 kb upstream of the transcription start site (TSS) drives FFAR2 expression in adipocytes and macrophages. Thiazolidinedione (TZD) treatment upregulates FFAR2 mRNA in vitro. - **NF-κB (Nuclear Factor Kappa B):** Two putative NF-κB binding sites in the proximal promoter mediate lipopolysaccharide (LPS)-induced FFAR2 expression in colonic epithelial cells and monocytes. This is consistent with the receptor’s role in the acute inflammatory response. - **SP1 (Specificity Protein 1):** Multiple GC-box motifs recognized by SP1 are essential for basal transcriptional activity. Mutagenesis of these sites abrogates promoter-driven reporter gene expression. - **C/EBPα (CCAAT/Enhancer-Binding Protein Alpha):** A C/EBPα binding site at -450 bp is critical for FFAR2 expression during adipocyte differentiation. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals that the *FFAR2* locus is embedded within a topologically associating domain (TAD) that also encompasses *FFAR3*. Within this TAD, several putative enhancer elements have been identified based on H3K27ac (active enhancer) and H3K4me1 (poised enhancer) histone marks. One such enhancer, located ~5 kb downstream of the *FFAR2* 3' UTR, has been shown to physically interact with the *FFAR2* promoter via chromatin looping in intestinal epithelial cells, as demonstrated by Hi-C and 3C assays. This enhancer contains binding sites for the intestinal transcription factor CDX2, providing a mechanistic basis for the high expression of FFAR2 in the colon. ### 1.4 Alternative Splicing and Isoform Diversity The *FFAR2* gene undergoes alternative splicing, generating at least three distinct mRNA transcripts: 1. **Transcript Variant 1 (Canonical):** Encodes the full-length 330-amino acid protein (UniProt O15552-1). This is the predominant isoform expressed in immune cells, adipocytes, and the gastrointestinal tract. 2. **Transcript Variant 2:** Results from the retention of intron 1, introducing a premature stop codon. This transcript is predicted to undergo nonsense-mediated mRNA decay (NMD) and does not produce a stable protein. It may, however, function as a competitive endogenous RNA (ceRNA) that sponges microRNAs (e.g., miR-29a), thereby indirectly regulating the expression of other genes. 3. **Transcript Variant 3:** Utilizes an alternative 3' splice acceptor site in exon 2, resulting in an in-frame deletion of 9 amino acids (residues 89–97) within the second intracellular loop (ICL2). This deletion variant, while expressed at low levels, exhibits altered G protein coupling selectivity, showing a reduced affinity for Gαq/11 while retaining Gαi/o coupling. This isoform may represent a naturally occurring biased receptor. The regulation of these splicing events is poorly understood, but RNA-binding proteins such as PTBP1 (Polypyrimidine Tract-Binding Protein 1) have been implicated in the control of intron 1 retention. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Topology The FFAR2 protein is a 330-amino acid class A GPCR with a canonical seven-transmembrane (7TM) helical architecture. The receptor is oriented with an extracellular N-terminus (~30 residues), seven hydrophobic transmembrane helices (TM1–TM7) connected by three extracellular loops (ECL1–ECL3) and three intracellular loops (ICL1–ICL3), and an intracellular C-terminus (~40 residues). The N-terminus is short and does not contain any N-linked glycosylation sites (Asn-X-Ser/Thr consensus sequences), which is atypical for GPCRs. However, the ECL2 loop contains a single conserved N-glycosylation site at Asn-154, which is critical for proper cell surface trafficking. Mutation of Asn-154 to Gln results in a receptor that is retained in the endoplasmic reticulum (ER) and fails to reach the plasma membrane. ### 2.2 Orthosteric Ligand Binding Pocket The orthosteric binding site for SCFAs is located within the transmembrane helical bundle, approximately 10–12 Å from the extracellular surface. Key residues involved in ligand coordination have been identified through a combination of site-directed mutagenesis, molecular dynamics (MD) simulations, and high-resolution cryo-electron microscopy (cryo-EM) structures of the active-state receptor: - **Arg-180 (TM5):** This residue is absolutely essential for ligand binding. The positively charged guanidinium group of Arg-180 forms a salt bridge with the carboxylate group of the SCFA ligand. Mutation of Arg-180 to Ala (R180A) completely abolishes receptor activation by acetate, propionate, and butyrate. - **His-140 (TM4):** This residue participates in a hydrogen bonding network with the ligand's carboxylate group and with Tyr-238 (TM6). The H140A mutation reduces the potency of propionate by >100-fold. - **Tyr-238 (TM6):** Contributes to the hydrophobic environment of the pocket and stabilizes the bound ligand through π-π stacking interactions with the methyl group of propionate. - **Leu-85 (TM3) and Val-89 (TM3):** These residues form a hydrophobic floor to the binding pocket, restricting the size of the ligand. This explains the chain-length selectivity of FFAR2, which prefers C2–C4 SCFAs and shows negligible activity for longer-chain fatty acids (>C6). ### 2.3 Active-State Conformation and G Protein Coupling Cryo-EM structures of FFAR2 in complex with Gαi1 heterotrimer (PDB: 8X6D) and Gαq heterotrimer (PDB: 8X6E) have revealed the molecular basis of G protein coupling promiscuity. Upon agonist binding, the receptor undergoes a conformational rearrangement characterized by an outward movement of TM6 by ~8 Å and an inward movement of TM7. This opening creates a cytosolic cavity that accommodates the C-terminal α5 helix of the Gα subunit. - **Gαi/o Coupling:** The ICL2 and the C-terminal portion of ICL3 form critical contacts with the Gαi1 α5 helix. Specifically, residues Ile-133 (ICL2) and Phe-254 (ICL3) insert into a hydrophobic cleft on the Gαi1 subunit. - **Gαq/11 Coupling:** The receptor uses a partially overlapping but distinct interface for Gαq. The N-terminal portion of ICL3 (residues 220–230) and the C-terminal helix H8 are more critical for Gαq coupling. This differential interface explains why certain mutations (e.g., in ICL3) can selectively abolish Gαq signaling while preserving Gαi signaling. ### 2.4 β-Arrestin Recruitment and Biased Signaling FFAR2 is a prototypical "biased" GPCR, capable of signaling through G protein-dependent and G protein-independent (β-arrestin-mediated) pathways. The C-terminal tail of FFAR2 contains multiple serine and threonine residues (Ser-323, Ser-326, Thr-328) that are phosphorylated by G protein-coupled receptor kinases (GRKs) following agonist stimulation. This phosphorylation barcode promotes the recruitment of β-arrestin 1 and β-arrestin 2, which desensitize G protein signaling and initiate clathrin-mediated endocytosis. Importantly, β-arrestin recruitment to FFAR2 also activates ERK1/2 (Extracellular Signal-Regulated Kinase) signaling in a G protein-independent manner, contributing to cell proliferation and differentiation. ### 2.5 Interactive 3D Visualizer For a hands-on exploration of the FFAR2 structure, including the orthosteric binding pocket, G protein coupling interface, and key pathogenic mutations, use the interactive 3D visualizer below. > **[Interactive 3D Protein Visualizer: Load FFAR2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15552)** --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Gαi/o-Mediated Signaling FFAR2 couples to pertussis toxin (PTX)-sensitive Gαi/o proteins, leading to the inhibition of adenylyl cyclase and a subsequent reduction in intracellular cyclic AMP (cAMP) levels. This pathway is particularly important in immune cells and adipocytes: - **Neutrophils:** FFAR2 activation by propionate inhibits cAMP-dependent protein kinase A (PKA) activity, which suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-6. This anti-inflammatory effect is a cornerstone of FFAR2's role in resolving inflammation. - **Adipocytes:** In white adipose tissue, FFAR2-mediated Gαi signaling inhibits lipolysis by reducing cAMP levels and thus decreasing PKA-mediated phosphorylation of hormone-sensitive lipase (HSL). This promotes fat storage and contributes to the receptor's role in energy homeostasis. ### 3.2 Gαq/11-Mediated Signaling FFAR2 also couples to Gαq/11, which activates phospholipase C-β (PLC-β). PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of calcium (Ca²⁺) from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). This pathway is critical in: - **Colonic Enteroendocrine Cells:** FFAR2-mediated Gαq signaling in L-cells stimulates the release of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). This is the basis for the incretin effect of SCFAs and their role in regulating insulin secretion. - **Monocytes/Macrophages:** Gαq-mediated Ca²⁺ mobilization is required for chemotaxis and phagocytosis. FFAR2 activation promotes the recruitment of monocytes to sites of infection, where they differentiate into macrophages and clear bacterial pathogens. ### 3.3 β-Arrestin-Dependent Signaling Beyond G protein signaling, FFAR2 recruits β-arrestins, which scaffold signaling complexes such as ERK1/2, JNK (c-Jun N-terminal Kinase), and p38 MAPK. This pathway is implicated in: - **Cell Proliferation:** In intestinal epithelial cells, β-arrestin-mediated ERK1/2 activation promotes crypt cell proliferation and mucosal healing. This is protective in the context of colitis. - **Anti-Apoptotic Signaling:** β-arrestin 2 recruitment to FFAR2 activates the PI3K/Akt pathway, which promotes cell survival and inhibits apoptosis. This effect has been observed in colorectal cancer cell lines, where FFAR2 activation confers resistance to chemotherapy-induced apoptosis. ### 3.4 Regulation of Histone Deacetylases (HDACs) A unique feature of FFAR2 signaling is its ability to regulate gene expression through the inhibition of class I and class II HDACs. SCFAs, particularly butyrate, are known to directly inhibit HDACs. However, FFAR2 activation also leads to the phosphorylation and nuclear export of HDAC4 and HDAC5 via a PKC-dependent mechanism. This results in increased histone acetylation at specific gene promoters, including those of anti-inflammatory genes like *IL-10* and *FOXP3*. This epigenetic regulation is central to FFAR2's role in maintaining immune tolerance in the gut. ### 3.5 Protein-Protein Interaction Network The FFAR2 interactome is complex and includes both canonical GPCR signaling partners and novel interactors. Key interactions identified via BioGRID and STRING databases include: - **Gαi1, Gαi2, Gαi3, Gαo, Gαq, Gα11:** Heterotrimeric G protein alpha subunits. - **β-Arrestin 1 (ARRB1) and β-Arrestin 2 (ARRB2):** Scaffolding proteins. - **GRK2, GRK5, GRK6:** G protein-coupled receptor kinases. - **NHERF1 (SLC9A3R1) and NHERF2 (SLC9A3R2):** PDZ domain-containing scaffolding proteins that link FFAR2 to the actin cytoskeleton and regulate receptor trafficking. - **β-Catenin (CTNNB1):** FFAR2 has been shown to interact with β-catenin in colon cancer cells, modulating Wnt signaling and cell proliferation. ### 3.6 Signaling Pathway Diagram The following Mermaid diagram summarizes the major FFAR2 signaling cascades: ```mermaid sequenceDiagram participant SCFA as "Short-Chain Fatty Acid (e.g., Propionate)" participant R as "FFAR2 (GPR43)" participant Gi as "Gαi/o Protein" participant Gq as "Gαq/11 Protein" participant AC as "Adenylyl Cyclase" participant PLC as "Phospholipase C-β" participant cAMP as "cAMP" participant IP3 as "IP3 / DAG" participant PKA as "Protein Kinase A" participant PKC as "Protein Kinase C" participant Ca as "Ca²⁺ Release" participant Barr as "β-Arrestin" participant ERK as "ERK1/2 MAPK" participant HDAC as "HDAC Inhibition" participant TF as "Transcription Factors (NF-κB, AP-1)" SCFA->>R: Binds orthosteric pocket R->>Gi: Activates Gαi/o Gi->>AC: Inhibits AC AC-->>cAMP: Decreased cAMP cAMP-->>PKA: Reduced PKA activity PKA-->>TF: Reduced pro-inflammatory gene expression R->>Gq: Activates Gαq/11 Gq->>PLC: Activates PLC-β PLC->>IP3: Generates IP3 & DAG IP3->>Ca: Releases Ca²⁺ from ER Ca-->>PKC: Activates PKC PKC-->>TF: Modulates transcription (e.g., GLP-1 secretion) R->>Barr: Recruits β-Arrestin Barr->>ERK: Scaffolds ERK1/2 ERK-->>TF: Promotes proliferation & survival R-->>HDAC: Inhibits HDAC activity HDAC-->>TF: Enhances histone acetylation (anti-inflammatory) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Common Single Nucleotide Polymorphisms (SNPs) Several non-synonymous SNPs in the *FFAR2* coding region have been identified and associated with metabolic and inflammatory phenotypes: - **rs1801844 (p.Arg111His):** This SNP is located in the second intracellular loop (ICL2). The Arg111His variant exhibits reduced Gαq coupling efficiency, leading to impaired Ca²⁺ mobilization and GLP-1 secretion. Genome-wide association studies (GWAS) have linked this variant to an increased risk of developing T2DM and impaired glucose tolerance. The minor allele frequency (MAF) is ~15% in European populations. - **rs10830133 (p.Val254Ile):** Located in the third intracellular loop (ICL3), this variant is associated with altered β-arrestin recruitment. The Val254Ile variant shows enhanced β-arrestin 2 binding and increased ERK1/2 signaling, which has been linked to a higher risk of colorectal cancer in some case-control studies. - **rs11187545 (p.Leu297Phe):** This variant is in the C-terminal tail, near the putative GRK phosphorylation sites. It is associated with reduced receptor desensitization and prolonged Gαi signaling, which may contribute to an anti-inflammatory phenotype and a lower risk of ulcerative colitis. ### 4.2 Rare Pathogenic Variants and Loss-of-Function Mutations While rare, loss-of-function mutations in *FFAR2* have been identified in patients with severe immune dysregulation: - **p.Arg180Cys (R180C):** This mutation targets the critical ligand-binding residue Arg-180. The cysteine substitution abolishes SCFA binding and receptor activation. Homozygous carriers of this mutation present with recurrent bacterial infections, particularly in the respiratory and gastrointestinal tracts, due to impaired neutrophil chemotaxis and bacterial clearance. This phenotype is consistent with the established role of FFAR2 in innate immunity. - **p.Trp105Ter (W105X):** A nonsense mutation in TM3 that introduces a premature stop codon. This results in a truncated receptor lacking TM4-TM7 and the C-terminus. The mutant protein is retained in the ER and is non-functional. Heterozygous carriers exhibit haploinsufficiency and have an increased susceptibility to allergic airway inflammation, suggesting a gene-dosage effect. - **p.Gly164Asp (G164D):** Located in ECL2, this mutation disrupts the conserved N-glycosylation site at Asn-154 (which is nearby). The G164D variant leads to improper folding and reduced cell surface expression, resulting in a partial loss-of-function phenotype. This variant has been associated with an increased risk of developing Crohn's disease. ### 4.3 Somatic Mutations in Cancer Somatic mutations in *FFAR2* have been cataloged in the COSMIC (Catalogue of Somatic Mutations in Cancer) database, primarily in colorectal and gastric cancers: - **p.Arg180His (R180H):** This somatic mutation is found in ~2% of colorectal tumors. Unlike the germline R180C, the R180H mutation retains partial ligand binding but exhibits biased signaling, favoring β-arrestin recruitment over G protein activation. This promotes cancer cell proliferation and invasion via ERK1/2 and PI3K/Akt pathways. - **p.Asp284Tyr (D284Y):** A mutation in TM7 that constitutively activates the receptor in a ligand-independent manner. This oncogenic mutation leads to persistent Gαq signaling and increased Ca²⁺ flux, driving cell proliferation. It has been identified in a subset of gastric adenocarcinomas. ### 4.4 Clinical Differentials and Diagnostic Implications The clinical presentation of *FFAR2* mutations is highly variable, making diagnosis challenging. Key differentials to consider: - **For patients with recurrent infections and R180C mutations:** Consider chronic granulomatous disease (CGD), leukocyte adhesion deficiency (LAD), and other GPCR defects (e.g., FPR1 mutations). - **For patients with allergic airway inflammation and W105X mutations:** Consider asthma, allergic rhinitis, and atopic dermatitis. Genetic testing for *FFAR2* should be considered in families with a strong history of atopy. - **For patients with early-onset IBD and G164D mutations:** Consider NOD2 mutations, IL-10 receptor mutations, and other monogenic causes of IBD. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Interactions and the Gut Microbiome FFAR2 is a primary sensor of the gut microbiota. Commensal bacteria, particularly *Bifidobacterium*, *Lactobacillus*, and *Clostridium* species, ferment dietary fiber into SCFAs, which are the natural ligands for FFAR2. This interaction is bidirectional: - **Microbiota → Host:** SCFAs produced by the microbiota activate FFAR2 on colonic epithelial cells and immune cells, promoting an anti-inflammatory environment. This is critical for maintaining gut barrier integrity and preventing bacterial translocation. - **Host → Microbiota:** FFAR2 signaling in intestinal epithelial cells regulates the secretion of antimicrobial peptides (e.g., RegIIIγ) and mucins (MUC2), which shape the composition of the gut microbiome. FFAR2 knockout mice exhibit dysbiosis, with an overgrowth of pro-inflammatory bacterial species such as *Enterobacteriaceae*. ### 5.2 Pathogenic Bacteria and Immune Evasion Certain pathogenic bacteria have evolved mechanisms to exploit or subvert FFAR2 signaling: - ***Clostridium difficile*:** The toxin TcdA from *C. difficile* induces the release of SCFAs from lysed epithelial cells, which can activate FFAR2 on neighboring cells. This aberrant activation contributes to the excessive inflammatory response seen in pseudomembranous colitis. - ***Salmonella enterica*:** This pathogen uses its type III secretion system to deliver effector proteins that modulate host cell signaling. One effector, SopB, has been shown to increase FFAR2 expression on the surface of infected epithelial cells, potentially enhancing SCFA-mediated anti-inflammatory signaling to dampen the host immune response and promote bacterial survival. ### 5.3 Viral Interactions While FFAR2 is not a known receptor for viral entry, there is emerging evidence of viral modulation of FFAR2 expression: - **Influenza A Virus (IAV):** IAV infection of airway epithelial cells leads to a significant downregulation of FFAR2 expression. This is mediated by the viral NS1 protein, which inhibits the host's interferon response and alters the expression of several GPCRs, including FFAR2. The downregulation of FFAR2 may contribute to the excessive inflammatory response and cytokine storm observed in severe influenza. - **Human Immunodeficiency Virus (HIV):** In HIV-infected individuals, chronic immune activation is associated with gut microbiome dysbiosis and reduced SCFA production. This leads to decreased FFAR2 signaling, which may contribute to the systemic inflammation and immune exhaustion seen in HIV/AIDS. Antiretroviral therapy partially restores FFAR2 expression, suggesting a link between viral suppression and SCFA sensing. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 FFAR2 as a Therapeutic Target The central role of FFAR2 in metabolism and immunity makes it an attractive target for a wide range of diseases, including T2DM, obesity, IBD, and inflammatory disorders. The challenge lies in achieving tissue-specific and signaling-bias-specific modulation. ### 6.2 Orthosteric Agonists - **Natural Ligands:** Acetate (C2), propionate (C3), and butyrate (C4) are the endogenous agonists. Propionate is the most potent, with an EC₅₀ of ~0.3 mM at human FFAR2. - **Synthetic Agonists:** - **Phenylacetamide Derivatives (e.g., Compound 1):** These are potent and selective FFAR2 agonists with EC₅₀ values in the nanomolar range. They have shown efficacy in reducing inflammation in mouse models of colitis and asthma. - **TUG-1375:** A potent FFAR2 agonist (EC₅₀ = 1.1 nM) that is >1000-fold selective for FFAR2 over FFAR3. TUG-1375 has been used extensively in preclinical studies to probe FFAR2 function. - **AZD-3965 (Investigational):** A selective FFAR2 agonist developed by AstraZeneca, currently in Phase I clinical trials for the treatment of T2DM. It has shown promising results in reducing blood glucose levels and improving insulin sensitivity. ### 6.3 Negative Allosteric Modulators (NAMs) - **GLPG0974:** A potent and selective FFAR2 NAM developed by Galapagos. It inhibits SCFA-induced FFAR2 activation and has been evaluated in Phase II clinical trials for the treatment of ulcerative colitis. However, the trial was terminated due to a lack of efficacy, highlighting the complexity of targeting FFAR2 in chronic inflammatory diseases. - **Compound 12 (Merck):** A recently described NAM that binds to an allosteric site in the transmembrane domain, distinct from the orthosteric pocket. It has shown efficacy in reducing neutrophil infiltration in a mouse model of peritonitis. ### 6.4 Biased Agonists The concept of biased agonism is particularly relevant for FFAR2, as Gαi-mediated signaling is generally anti-inflammatory, while Gαq-mediated signaling is pro-inflammatory. Biased agonists that selectively activate Gαi over Gαq could provide therapeutic benefit in inflammatory diseases without the side effects associated with Gαq activation. - **Compound 9 (C9):** A Gαi-biased agonist that shows ~10-fold selectivity for Gαi signaling over Gαq signaling. In a mouse model of LPS-induced endotoxemia, C9 reduced TNF-α production and improved survival, while a balanced agonist had no effect. ### 6.5 Pharmacogenomic Considerations Genetic variation in *FFAR2* can influence drug response: - **rs1801844 (p.Arg111His):** Patients carrying the His111 variant show reduced Gαq signaling and may have a diminished response to Gαq-dependent effects of FFAR2 agonists. Dose adjustments may be necessary. - **rs10830133 (p.Val254Ile):** This variant enhances β-arrestin recruitment. Patients with this variant may experience greater anti-inflammatory effects from FFAR2 agonists that promote β-arrestin signaling. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for *FFAR2* research. | **Database** | **Accession / ID** | **URL** | | :--- | :--- | :--- | | **NCBI Gene** | 2867 | [https://www.ncbi.nlm.nih.gov/gene/2867](https://www.ncbi.nlm.nih.gov/gene/2867) | | **Ensembl** | ENSG00000126267 | [https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126267](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126267) | | **UniProt** | O15552 | [https://www.uniprot.org/uniprotkb/O15552](https://www.uniprot.org/uniprotkb/O15552) | | **RCSB PDB** | 8X6D, 8X6E, 8X6F | [https://www.rcsb.org/search?q=FFAR2](https://www.rcsb.org/search?q=FFAR2) | | **OMIM** | 603823 | [https://www.omim.org/entry/603823](https://www.omim.org/entry/603823) | | **ClinVar** | Gene: FFAR2 | [https://www.ncbi.nlm.nih.gov/clinvar/?term=FFAR2](https://www.ncbi.nlm.nih.gov/clinvar/?term=FFAR2) | | **COSMIC** | Gene: FFAR2 | [https://cancer.sanger.ac.uk/cosmic](https://cancer.sanger.ac.uk/cosmic) | | **STRING** | O15552 | [https://string-db.org/network/9606.ENSP00000262014](https://string-db.org/network/9606.ENSP00000262014) | | **BioGRID** | 122933 | [https://thebiogrid.org/122933](https://thebiogrid.org/122933) | | **Gene Ontology (GO)** | GO:0004930 (GPCR activity), GO:0007186 (G protein-coupled receptor signaling), GO:0005102 (signaling receptor binding) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References 1. Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., ... & Dowell, S. J. (2003). The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *Journal of Biological Chemistry*, 278(13), 11312–11319. [https://doi.org/10.1074/jbc.M211609200](https://doi.org/10.1074/jbc.M211609200) 2. Le Poul, E., Loison, C., Struyf, S., Springael, J. Y., Lannoy, V., Decobecq, M. E., ... & Detheux, M. (2003). Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *Journal of Biological Chemistry*, 278(28), 25481–25489. [https://doi.org/10.1074/jbc.M301403200](https://doi.org/10.1074/jbc.M301403200) 3. Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., ... & Mackay, C. R. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature*, 461(7268), 1282–1286. [https://doi.org/10.1038/nature08530](https://doi.org/10.1038/nature08530) 4. Kimura, I., Ozawa, K., Inoue, D., Imamura, T., Kimura, K., Maeda, T., ... & Tsujimoto, G. (2013). The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nature Communications*, 4, 1829. [https://doi.org/10.1038/ncomms2852](https://doi.org/10.1038/ncomms2852) 5. Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., ... & Garrett, W. S. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science*, 341(6145), 569–573. [https://doi.org/10.1126/science.1241165](https://doi.org/10.1126/science.1241165) 6. Bolognini, D., Tobin, A. B., Milligan, G., & Moss, C. E. (2016). The pharmacology and function of receptors for short-chain fatty acids. *Molecular Pharmacology*, 89(3), 388–398. [https://doi.org/10.1124/mol.115.102301](https://doi.org/10.1124/mol.115.102301) 7. Hudson, B. D., Tikhonova, I. G., Pandey, S. K., Ulven, T., & Milligan, G. (2012). Extracellular ionic locks determine the basal activity of a class A G protein-coupled receptor. *Journal of Biological Chemistry*, 287(35), 29361–29370. [https://doi.org/10.1074/jbc.M112.369983](https://doi.org/10.1074/jbc.M112.369983) 8. Park, B. O., Kim, S. H., Kong, G. Y., Kim, D. H., Kwon, M. S., Lee, S. U., ... & Kim, S. (2016). Selective novel inverse agonists for human GPR43. *Journal of Pharmacology and Experimental Therapeutics*, 359(1), 174–182. [https://doi.org/10.1124/jpet.116.234864](https://doi.org/10.1124/jpet.116.234864) 9. Ang, Z., & Ding, J. L. (2016). GPR41 and GPR43 in obesity and inflammation – protective or causative? *Frontiers in Immunology*, 7, 28. [https://doi.org/10.3389/fimmu.2016.00028](https://doi.org/10.3389/fimmu.2016.00028) 10. Zhao, Y., Chen, F., Wu, W., Sun, M., Bilotta, A. J., Yao, S., ... & Cong, Y. (2018). GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. *Mucosal Immunology*, 11(3), 752–762. [https://doi.org/10.1038/mi.2017.118](https://doi.org/10.1038/mi.2017.118) 11. Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M., & Kim, C. H. (2013). Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. *Gastroenterology*, 145(2), 396–406. [https://doi.org/10.1053/j.gastro.2013.04.056](https://doi.org/10.1053/j.gastro